Pieris Pharma nabs $20M upfront from Roche's Genentech for respiratory, ophthalmology pact Bristol Myers taps Xencor’s half-life tech for COVID-19 antibody Mexico ramping up COVID-19 trial work tapping Sanofi, China's shots in late-stage tests New JV from upstart biotechs Pyxis, Alloy aims for rapid drug development in cancer, autoimmune diseases Xilio inks Merck deal to run checkpoint inhibitor combo trial GenSight's mutation-agnostic gene therapy triggers partial vision recovery Pharmacy giant CVS Health launches new clinical trial services biz, eyes siteless trials platform A 'springboard' to the future: Genentech, Sanofi and Alnylam execs sound off on pharma's evolving back-to-work plans Featured Story | By Kyle LaHucik Pieris Pharmaceuticals has tapped another Big Pharma in its collaboration efforts, this time striking a $20 million upfront deal with Roche's Genentech. read more |
| |
|---|
|
Top Stories By Amirah Al Idrus Bristol Myers Squibb was a late entrant to the COVID-19 therapeutics space, picking up a pair of antibody treatments from Rockefeller University in February this year. Now, as the combination makes its way through phase 1 trials, the Big Pharma is licensing technology from Xencor that extends the treatment’s half-life. read more By Ben Adams French Big Pharma Sanofi, using its traditional vaccine approach, and Chinese biotech Walvax, using mRNA technology, are both set to start phase 3 trials in Mexico. read more By Annalee Armstrong Kyma Therapeutics from Alloy Therapeutics and Pyxis Oncology will work on immune-modulating targets selected in cancer and autoimmune diseases. The candidates will be developed to what Alloy and Pyxis call a “value-inflection point,” at which point the companies expect they will be eligible for independent funding and partnering with other pharmas. read more By Nick Paul Taylor Xilio Therapeutics has struck a deal with Merck to test its anti-CTLA-4 monoclonal antibody XTX101 in combination with Keytruda. The agreement sets Xilio up to show whether it can combine the checkpoint inhibitors without causing the toxicities associated with other cocktails that target CTLA-4 and PD-1. read more By Nick Paul Taylor GenSight Biologics has reported the partial recovery of the vision of a retinitis pigmentosa patient treated with its mutation-independent approach to the restoration of visual function. read more By Ben Adams CVS Health has navigated a pandemic that decimated footfall into its pharmacies but boosted demand for diagnostics and also saw it help pharma companies and CROs find trial subjects for COVID-19 tests. read more By Fraiser Kansteiner,Noah Higgins-Dunn,Eric Sagonowsky Top pharma HR executives know that bringing the work-from-home crowd back to the office is a chance to completely rethink how and where people do their jobs. In interviews, execs from three drugmakers—Sanofi, Alnylam and Genentech—explained how their companies are doing just that. read more Resources Sponsored by: BBK Worldwide Create a more diverse and inclusive clinical trial enrollment and engagement environment by learning the barriers to participation and the strategies to overcome them. Sponsored by: Thermo Fisher Scientific Autologous cell and gene therapy workflows involve isolating cells from an individual, engineering the cells, expanding and concentrating them, and infusing them back into the patient. Optimized automation of certain steps of the workflow may decrease hands-on time and the cost of the cell manufacturing process. Sponsored By: Veeva Learn how to develop a standards program that has your full team’s buy-in and improves the efficiency and quality of your clinical trials. Sponsored By: Veeva One top 10 pharma outlines three key steps to launching a modular content strategy to generate localized content faster. Sponsored By: Blue Matter This 77-page e-book explores 7 keys to success that any biopharma company needs to keep in mind as it enters Europe. Sponsored by: Datacubed Health The average clinical trial spends $40,000 per patient. Yet despite these high costs, most trials struggle to retain patients. Sponsored By: AmerisourceBergen Developing a quality product and getting it approved for distribution is not enough to guarantee commercial success. Sponsored By: WCG Trifecta The new standards in study training help sponsors and CROs reduce costs by 60%, cut training time by 50%, and start enrollment 55 days faster – learn more today. Sponsored by: Cytiva A one-stop hub for Cytiva resources to support process intesification Sponsored By: August Bioservices How has COVID-19 impacted CRO/CDMO customer (dis)satisfaction and outsourcing decisions for pharma and biotech companies in 2021 and beyond? Sponsored by: Cytiva A one-stop hub for Cytiva resources to support process development and manufacturing of your novel molecule Sponsored by: TAC Roche has inked a $1.8 billion, all-cash deal for GenMark Diagnostics, to acquire its molecular tests designed to screen patient samples for multiple infections simultaneously. Sponsored By: Remarque Systems Remarque Systems consolidates data, then layers on visualization and automated metrics to generate consistent, actionable data insights in real-time. Click here for more info. Sponsored By: Oracle Health Sciences New research indicates an accelerated adoption of decentralized clinical trials due to COVID-19. Sponsored by: Catalent Autologous cell therapies have seen propelled growth since 2017, with the spotlight on the first FDA approval of a chimeric antigen receptor (CAR) T cell immunotherapy, Kymriah® (tisagenlecleucel), for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia. Sponsored by: Catalent Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase. Sponsored by: Catalent Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent. Sponsored by: Catalent In a BioPharma Dive industry survey, planning and forecasting were identified as top concerns for trial sponsors. In response to this need, the CSM team at Catalent has developed a methodology for identifying, evaluating, and proactively managing the inherent risks involved in clinical trial supply chain management. Sponsored by: Catalent Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study. Drug Development Boot Camp® 2021 Onsite and VIRTUAL in real time November 17-18, 2021 | Register now! Pre-Boot Camp preparation is now available. Vaccines, cell and gene therapy, antibodies, and RNA-based drugs June 10-11, 2021 | 9 a.m. EST / 6 a.m. PST Next Gen: What’s beyond the leading edge of biotech and pharma? June 22-23, 2021 | Virtual Event Biopharma Supply Chain June 29-30, 2021 | Virtual Event | 